angiotensin converting enzyme inhibitor, benazepril (20 mg/d)
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2006 Jan 12;354(2):131-40 Randomized Controlled Trial
IN kidney disease, chronic, non diabetic, severe The Use of
angiotensin converting enzyme inhibitor, benazepril (20 mg/d)
As Treatment, Chronic
Is better Than
placebo
To reduce progession (doubling initial creatinine or end-stage renal failure) at 3.4 years: 60% with placebo VS 41% using benazepril. Hypertension control was similar, proteinuria was reduced